Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
Read More
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
Read More
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
Read More
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
Read More
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
Read More
Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation
Read More
Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
Read More
FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma
Read More
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer
Read More
Krazati Received Accelerated FDA Approval for NSCLC with KRAS G12C Mutation
Read More
1
2
3
4
5
6
7
Page 4 of 26
Results 31 - 40 of 253